1225453-72-4

1225453-72-4 structure

Name: Lumiracoxib-d6
Chemical Name: Lumiracoxib-d6
CAS Number: 1225453-72-4
Molecular Formula: C₁₅H₇D₆ClFNO₂
Molecular Weight: 299.76
Catalog: Signaling Pathways Immunology/Inflammation COX
Create Date: 2021-10-28 17:55:07
Modify Date: 2024-01-09 18:18:04
Lumiracoxib-d6 (COX-189-d6) is the deuterium labeled Lumiracoxib. Lumiracoxib is a potent,selective and orally active COX-2 inhibitor with a Ki value of 0.06 μM[1]. Lumiracoxib acts as a nonselective NSAID with anti-inflammatory, analgesic and antipyretic activities. Lumiracoxib can be used for osteoarthritis and bone cancer research[1][2].

Name	Lumiracoxib-d6

Description	Lumiracoxib-d6 (COX-189-d6) is the deuterium labeled Lumiracoxib. Lumiracoxib is a potent,selective and orally active COX-2 inhibitor with a Ki value of 0.06 μM[1]. Lumiracoxib acts as a nonselective NSAID with anti-inflammatory, analgesic and antipyretic activities. Lumiracoxib can be used for osteoarthritis and bone cancer research[1][2].
Related Catalog	Research Areas >> Cancer Research Areas >> Inflammation/Immunology Signaling Pathways >> Immunology/Inflammation >> COX Research Areas >> Metabolic Disease
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Ronald Esser, et al. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br J Pharmacol. 2005 Feb;144(4):538-50. [3]. Alyson Fox, et al. Anti-hyperalgesic activity of the cox-2 inhibitor lumiracoxib in a model of bone cancer pain in the rat. Pain

Molecular Formula	C₁₅H₇D₆ClFNO₂
Molecular Weight	299.76